CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Total revenues	$ 633,519	$ 884,322
Cost of revenues	232,031	153,485
Operating expenses:
Selling, general and administrative	2,373,413	3,082,380
Research and development	564,426	709,564
Depreciation and amortization	75,067	135,052
Total operating expenses	3,012,906	3,926,996
LOSS FROM OPERATIONS	(2,611,418)	(3,196,159)
Other (expense) income:
Interest (expense) income, net (including related party of $23,470 for the three month period ended December 31, 2018)	(29,091)	(31,611)
Other expense, net	(22,232)	(6,550)
Loss before provision for income taxes	(2,662,741)	(3,234,320)
Provision for income taxes	0	0
NET LOSS	(2,662,741)	(3,234,320)
Less: Net loss attributable to noncontrolling interest	30
NET LOSS attributable to Applied DNA Sciences, Inc.	(2,662,711)	(3,234,320)
Deemed dividend related to warrant modifications	(2,842)
NET LOSS applicable to common stockholders	$ (2,665,553)	$ (3,234,320)
Net loss per share applicable to common stockholders-basic and diluted	$ (1.12)	$ (4.25)
Weighted average shares outstanding-basic and diluted (in shares)	2,380,564	761,769
Product
Revenues:
Total revenues	$ 237,870	$ 321,875
Service
Revenues:
Total revenues	$ 395,649	$ 562,447